Standout Papers

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study 2025 202617
  1. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study (2025)
    Richard Finn, Baek‐Yeol Ryoo et al. The Lancet Oncology

Immediate Impact

50 standout
Sub-graph 1 of 25

Citing Papers

Energy metabolism in health and diseases
2025 Standout
Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation
2025 Standout
2 intermediate papers

Works of Matthew H. Secrest being referenced

Prevalence of pyruvate kinase deficiency: A systematic literature review
2020
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
2017

Author Peers

Author Last Decade Papers Cites
Matthew H. Secrest 37 106 147 76 18 390
Linyan Wei 36 38 168 63 26 455
Xiang Bu 22 39 171 61 18 423
Hanyang Lin 83 37 80 82 10 354
Chien‐Hua Tseng 55 24 102 154 35 434
Claire Sampankanpanich Soria 6 49 110 147 20 356
Zhenyu Wu 126 31 130 47 44 411
Yudiyang Ma 6 36 202 36 43 424
Emma Coady 9 36 55 44 14 387
Xiangxiang Jiang 59 34 122 58 19 400
Dian He 13 26 101 18 28 358

All Works

Loading papers...

Rankless by CCL
2026